Propafenone Hydrochloride Injection Receives Drug Production Registration Certificate
January 30, 2026
Source: https://finance.eastmoney.com/a/202601303636739215.html
31
On January 30th, Shijiazhuang Pharmaceutical Group announced on the Hong Kong Stock Exchange that it had obtained the drug production registration certificate from the National Medical Products Administration of China for propafenone hydrochloride injection (20ml:70mg). This drug is classified as a Class 3 chemical drug and is considered to have passed the consistency evaluation. Shijiazhuang Pharmaceutical Group is the third domestic company to receive this approval. Propafenone hydrochloride injection is mainly used for treating supraventricular tachycardia, such as atrioventricular junctional tachycardia, WPW syndrome complicated with supraventricular tachycardia or paroxysmal atrial fibrillation, and ventricular tachycardia requiring treatment or that may be fatal.
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Initial Clinical Exploration of D-0502 in Combination with ADC Therapies Officially Commenced. January 30, 2026
- Pfizer’s blockbuster drug receives notice of approval! January 30, 2026
- Aminophylline tablets pass generic drug consistency evaluation January 30, 2026
- Hengrui’s innovative drug camrelizumab in combination with apatinib mesylate and TACE for the treatment of liver cancer has been accepted for marketing authorization application January 30, 2026
- The world’s first clinically approved “autologous regenerated islets” for the treatment of type 2 diabetes! Ruipuchen Chuang opens a new dual-indication autologous regeneration track. January 30, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
